Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, Aledex, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Post by skyhi0on Nov 29, 2006 3:26pm
183 Views
Post# 11773333

Sounds like....

Sounds like........ the product is or will be in the finishing and polishing room..... from the news below.... I think the question may be... What is the activity currently underway towards that end? (providing we don't get taken out before then) "To perform this well with our prototype, against the leading product on the market, is a tremendous achievement; especially as we can expect even better results with our final optimized product", stated Mr. Gord Froehlich, President of Kane Biotech Inc. "In fact, Kane has performed in vitro studies that demonstrate KBI-4258 is superior to the market leading coated catheter not only against S. aureus, but also against Staphylococcus epidermidis and Candida albicans, the three most significant pathogens in catheter related blood stream infections."
Bullboard Posts